Year-end Report 2018

The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]

Xintela publishes results from stem cell study

Lund, Sweden, 15 February 2019 – Xintela announces that results from studies characterizing stem cells, isolated from horse and selected with Xintela’s marker technology, have now been published in the international scientific journal Annals of Stem Cell Research.  The publication demonstrates and discuss the functional advantages of Xintela’s selected stem cells. Xintela has previously reported […]

A successful year

Xintela had a very eventful year with success regarding both projects and financing. The following presentation summarises the status of Xintela’s various activities and overall plans for the coming year. Through a directed issue of approximately MSEK 50 to the German orthopaedic company Bauerfeind AG, we achieved financial stability and a long-term owner with a […]

Xintela at partnering conferences

Xintela has worked intensively to connect the company with potential partners and international investors. Thomas Areschoug, Business Development Manager at Xintela, tells more about the conferences that the company attended during the autumn. Xintela participated in a number of partnering conferences during the autumn. First of all, why it is so important for Xintela to […]

Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers

Lund, Sweden, 8 January 2019 – Xintela announces today that the company’s international (PCT) patent application for quality-assured chondrocytes (cartilage cells), developed using the company’s integrin markers, was published on January 3, 2019 under publication number WO 2019/002547. The patent application relates to a further development of Xintela’s marker technology and quality test XACT and […]

Xintela and Catalent to co-develop brain cancer therapy

Lund, Sverige, 25 oktober 2018 – Xintela tillkännager idag att bolaget har tecknat ett samarbetsavtal med det amerikanska bolaget Redwood BioScience Inc, ett helägt dotterbolag till Catalent, Inc., världsledande inom antibody-drug conjugate (ADC) teknologi för cancerterapi. Parterna avser att gemensamt utveckla en ADC-baserad terapeutisk produkt med första inriktning på hjärntumören glioblastom, den vanligaste och mest […]

SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]

XINTELA TO SPIN OUT ONCOLOGY BUSINESS

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]